Welcome and Introductions
Kathleen Moore, MD
Our Expert Panel

Kathleen Moore, MD
Stephenson Cancer Center, University of Oklahoma

Isabelle Ray-Coquard, MD, PhD
Centre Leon Bérard

Linda Duska, MD, MPH
Emily Couric Clinical Cancer Center, UVA Health

Róisín O’Cearbhaill, MD
Memorial Sloan Kettering Cancer Center
# Disclosures

## Faculty

<table>
<thead>
<tr>
<th>Name</th>
<th>Honoraria (personal)</th>
<th>Honoraria (institution)</th>
<th>Funding (institution)</th>
<th>Principal investigator</th>
<th>President</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Isabelle Ray-Coquard, MD, PhD</strong></td>
<td>Adaptimmune, Agenus, Amgen, AstraZeneca, BMS, Clovis, Daiichi Sankyo, Deciphera, Eisai, EQRx, GSK, MacroGenics, Merck Serono, Mersana, Novartis, Onxeo, Roche, Sutro Biopharma</td>
<td>MSD (translational research)</td>
<td>BMS</td>
<td>PAOLA-1 (unrecompensed)</td>
<td>GINECO (unrecompensed)</td>
</tr>
<tr>
<td><strong>Kathleen Moore, MD</strong></td>
<td>AstraZeneca Pharmaceuticals, Aadi Bioscience, Aravive Inc, Alkermes, Blueprint Medicines, Clovis Oncology, Caris Life Sciences, DualityBio, Eisai Inc, Genentech—a member of Roche group, GSK, Hengrui Therapeutics Inc, ImmunoGen, InxMed, J-Mab, Janssen, Lilly, Mersana, Mereo BioPharma, Myriad Genetic Laboratories Inc, Merck, Novartis, Onconova Therapeutics Inc., OncXerna Therapeutics, Panavance Therapeutics, Regeneron Pharmaceuticals Inc., VBL Therapeutics, Verastem Oncology, Zentalis Pharmaceuticals</td>
<td>MSD</td>
<td>BMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Linda Duska, MD, MPH</strong></td>
<td>Aadi Bioscience and Regeneron, Fees (to institution): Merck</td>
<td>Merck</td>
<td>Merck</td>
<td>AD: GOG-P and BOD for ASCO and GOG-F</td>
<td></td>
</tr>
<tr>
<td><strong>Róisín O'Ceirbhail, MD</strong></td>
<td>MJH Life Sciences, Curio BioScience, OncLive/PER and GOG Foundation</td>
<td>Merck</td>
<td>Merck</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Consulting or Advisory Role

- **Isabelle Ray-Coquard, MD, PhD**: Bayer, ImmunoGen, Regeneron Pharmaceuticals, Inc., Seattle Genetics and Tesaro/GlaxoSmithKline, Miltenyi Biotec, 2seventy bio
- **Kathleen Moore, MD**: Genentech/Roche, AbbVie/(GOG 3005), Acrivon, Advaxis, Aduro BioTech, Alkermes, Blueprint, Constellation, Eisai, GSK/Novartis, Immunogen, Inovio, Iovance, Karyopharm, KSQ Therapeutics, Lycera, Merck, Morab, MorphoTek, Naveris, Nurix, OncoQuest, Pfizer, Syndax, Tesaro, Zentalis

## Research funding (to institution)

- **Isabelle Ray-Coquard, MD, PhD**: AbbVie/Stemcentrx, Alkermes, ArsenalBio, Atara Biotherapeutics, Bayer/Celgene/Juno, Genentech, Genmab/Seagen, GOG-F, Kite Pharma, Lyell Immunopharma, Ludwig Cancer Research, Marker Therapeutics, Merck, Regeneron Pharmaceuticals Inc., SELLAS Life Sciences Group, Syndax Pharmaceuticals, TCR2 Therapeutics, Lyell Immunopharma, Inc., and Tesaro/GSK.
<table>
<thead>
<tr>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
</table>
| Welcome and Introduction                                            | Kathleen Moore, MD  
Stephenson Cancer Center, University of Oklahoma                          |
| ADC Opportunities in Ovarian Cancer                                  | Isabelle Ray-Coquard, MD, PhD  
Centre Leon Bérard                                                           |
| Patient-Focused Treatment Quality of Life With ADCs: The ABCs of ADCs for Patient Care | Linda Duska, MD, MPH  
Emily Couric Clinical Cancer Center, UVA Health                             |
| Panel Discussion: Available Treatments and Most Active Target/Payload Combination | All Faculty  
(Moderator: Kathleen Moore, MD)                                           |
| Important Advancements in Clinical Trial Development: How Lessons Learned Influence and Shape Future Opportunities | Róisín O'Cearbhaill, MD  
Memorial Sloan Kettering Cancer Center                                         |
| Panel Discussion and Audience Q&A                                    | All Faculty  
(Moderator: Kathleen Moore, MD)                                           |